PMID- 35799397
OWN - NLM
STAT- MEDLINE
DCOM- 20220711
LR  - 20231213
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 49
IP  - 6
DP  - 2022 Jun
TI  - [Comparative Safety Assessment of Ramucirumab plus FOLFIRI and Bevacizumab plus 
      FOLFIRI in Second- and Later-Line Treatment in Japanese Patients with Metastatic 
      Colorectal Carcinoma].
PG  - 687-691
AB  - The addition of anti-angiogenic agents to cytotoxic agents to improve outcomes 
      has become the standard treatment for metastatic colorectal carcinoma. In this 
      study, we evaluated the safety of bevacizumab plus FOLFIRI with that of 
      ramucirumab plus FOLFIRI in second- and later-line treatment in Japanese patients 
      with metastatic colorectal carcinoma. Patients who received ramucirumab or 
      bevacizumab as a second- and later-line treatment between January 2016 and March 
      2020 were included. Treatment regimens, body surface area, dosage, number of 
      treatment courses, and adverse events( AEs) were evaluated. There were 66 and 17 
      patients in the bevacizumab plus FOLFIRI and ramucirumab plus FOLFIRI groups, 
      respectively. All patients developed AEs. AEs of grade 3/4 were documented in 
      84.8% and 100% of the patients in the bevacizumab plus FOLFIRI and ramucirumab 
      plus FOLFIRI groups, respectively. Progressive disease was the most common reason 
      for treatment discontinuation in both groups. Twelve (18.2%) and 5 (29.4%) 
      patients in the bevacizumab plus FOLFIRI and ramucirumab plus FOLFIRI groups, 
      respectively, discontinued treatment due to AEs. The most common AEs leading to 
      discontinuation were malaise and decreased performance status. The findings of 
      our study indicated that both bevacizumab plus FOLFIRI and ramucirumab plus 
      FOLFIRI groups have a high incidence of AEs, and that medical professionals need 
      to be aware of the frequent development of malaise and decreased performance 
      status.
FAU - Iwai, Mina
AU  - Iwai M
AD  - Dept. of Pharmacy, Ogaki Municipal Hospital.
FAU - Kimura, Michio
AU  - Kimura M
FAU - Usami, Eiseki
AU  - Usami E
FAU - Yoshimura, Tomoaki
AU  - Yoshimura T
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - Q573I9DVLP (Leucovorin)
RN  - U3P01618RT (Fluorouracil)
RN  - XT3Z54Z28A (Camptothecin)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Bevacizumab
MH  - *Camptothecin
MH  - *Colorectal Neoplasms/drug therapy/pathology
MH  - Fluorouracil
MH  - Humans
MH  - Japan
MH  - Leucovorin
MH  - Neoplasm Metastasis
MH  - Ramucirumab
EDAT- 2022/07/09 06:00
MHDA- 2022/07/12 06:00
CRDT- 2022/07/08 01:13
PHST- 2022/07/08 01:13 [entrez]
PHST- 2022/07/09 06:00 [pubmed]
PHST- 2022/07/12 06:00 [medline]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2022 Jun;49(6):687-691.